{"id":6846,"date":"2010-05-14T11:31:43","date_gmt":"2010-05-14T09:31:43","guid":{"rendered":"http:\/\/www.taxresearch.org.uk\/Blog\/2010\/05\/14\/profits-everywhere-except-near-the-tax-man\/"},"modified":"2010-05-14T11:31:43","modified_gmt":"2010-05-14T09:31:43","slug":"profits-everywhere-except-near-the-tax-man","status":"publish","type":"post","link":"https:\/\/www.taxresearch.org.uk\/Blog\/2010\/05\/14\/profits-everywhere-except-near-the-tax-man\/","title":{"rendered":"Profits everywhere &ndash; except near the tax man"},"content":{"rendered":"<p>There&rsquo;s a <a href=\"http:\/\/www.bloomberg.com\/apps\/news?pid=20601109&amp;sid=aEfZbpkSLCBQ\" target=\"_blank\">second article from Jesse Drucker<\/a> in Bloomberg today. It reports:<\/p>\n<blockquote>\n<p>Over the past three years, <a href=\"http:\/\/www.bloomberg.com\/apps\/quote?ticker=PFE%3AUS\">Pfizer Inc<\/a>. was an earner without profit in its own country.<\/p>\n<p>The maker of the cholesterol medication Lipitor, the world&rsquo;s top-selling prescription drug, reported almost half its revenues in the U.S. for 2007 through 2009, while booking domestic pretax losses totaling $5.2 billion.<\/p>\n<p>Abroad, it was another story. A Dutch subsidiary more than made up for New York-based Pfizer&rsquo;s American losses. It reported pretax profits totaling $20.4 billion in 2007 and 2008 -- with a tax expense of 5 percent, a seventh of the top U.S. rate. Overseas tax savings increased the drugmaker&rsquo;s <a href=\"http:\/\/www.bloomberg.com\/apps\/quote?ticker=PFE%3AUS\">net income<\/a> by $1 billion last year, according to <a href=\"http:\/\/search.bloomberg.com\/search?q=Robert+Willens&amp;site=wnews&amp;client=wnews&amp;proxystylesheet=wnews&amp;output=xml_no_dtd&amp;ie=UTF-8&amp;oe=UTF-8&amp;filter=p&amp;getfields=wnnis&amp;sort=date:D:S:d1\">Robert Willens<\/a>, a tax consultant in New York.<\/p>\n<p>Pfizer is one of thousands of American companies that bolster their profits by attributing income to subsidiaries in countries with lower income tax rates, legally cutting their tax bills. <a href=\"http:\/\/www.bloomberg.com\/apps\/quote?ticker=LLY%3AUS\">Eli Lilly &amp; Co<\/a>. and <a href=\"http:\/\/www.bloomberg.com\/apps\/quote?ticker=ORCL%3AUS\">Oracle Corp.<\/a> were among other big companies that helped drive a 70 percent increase in accumulated earnings abroad that weren&rsquo;t taxed in the U.S. from 2006 to 2009, according to data compiled by Bloomberg.<\/p>\n<p>&ldquo;An inordinate concentration of profits in a low-tax country, way out of proportion to actual economic activity, is a sure sign of aggressive tax planning,&rdquo; said <a href=\"http:\/\/search.bloomberg.com\/search?q=Martin+Sullivan&amp;site=wnews&amp;client=wnews&amp;proxystylesheet=wnews&amp;output=xml_no_dtd&amp;ie=UTF-8&amp;oe=UTF-8&amp;filter=p&amp;getfields=wnnis&amp;sort=date:D:S:d1\">Martin Sullivan<\/a>, a tax economist who formerly worked for the U.S. Treasury and Arthur Andersen LLP.<\/p>\n<\/blockquote>\n<p>Martin is a great guy.<\/p>\n<p>He&rsquo;s never wrong on these issues.<\/p>\n<p>This is the economic reality of globalisation. <\/p>\n<p>We could shatter it with <a href=\"http:\/\/www.financialtaskforce.org\/wp-content\/uploads\/2009\/06\/Final_CbyC_Report_Published.pdf\" target=\"_blank\">country-by-country reporting<\/a>.<\/p>\n<p>That would shift some of the burden of the <a href=\"http:\/\/www.taxresearch.org.uk\/Blog\/2010\/05\/14\/tax-increases-of-2000-a-taxpayer-coming-your-way-soon\/\" target=\"_blank\">tax increases we&rsquo;re going to have<\/a> back onto capital.<\/p>\n<p>What are we waiting for? <\/p>\n","protected":false},"excerpt":{"rendered":"<p>There&rsquo;s a second article from Jesse Drucker in Bloomberg today. It reports: Over the past three years, Pfizer Inc. was an earner without profit in<br \/><a class=\"moretag\" href=\"https:\/\/www.taxresearch.org.uk\/Blog\/2010\/05\/14\/profits-everywhere-except-near-the-tax-man\/\"><em> Read the full article&#8230;<\/em><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[79,35,32,48,51],"tags":[],"class_list":["post-6846","post","type-post","status-publish","format-standard","hentry","category-country-by-country","category-economics","category-tax-havens","category-tax-planning","category-transfer-pricing"],"_links":{"self":[{"href":"https:\/\/www.taxresearch.org.uk\/Blog\/wp-json\/wp\/v2\/posts\/6846","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.taxresearch.org.uk\/Blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.taxresearch.org.uk\/Blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.taxresearch.org.uk\/Blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.taxresearch.org.uk\/Blog\/wp-json\/wp\/v2\/comments?post=6846"}],"version-history":[{"count":0,"href":"https:\/\/www.taxresearch.org.uk\/Blog\/wp-json\/wp\/v2\/posts\/6846\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.taxresearch.org.uk\/Blog\/wp-json\/wp\/v2\/media?parent=6846"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.taxresearch.org.uk\/Blog\/wp-json\/wp\/v2\/categories?post=6846"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.taxresearch.org.uk\/Blog\/wp-json\/wp\/v2\/tags?post=6846"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}